VYONDYS 53 Drug Patent Profile

When do Vyondys 53 patents expire, and when can generic versions of Vyondys 53 launch?

Vyondys 53 is a drug marketed by Sarepta Theraps Inc and is included in one NDA. There is one patent protecting this drug.

This drug has thirty patent family members in thirteen countries.

The generic ingredient in VYONDYS 53 is golodirsen. One supplier is listed for this compound. Additional details are available on the golodirsen profile page.

DrugPatentWatch^® Generic Entry Outlook for Vyondys 53

Vyondys 53 was eligible for patent challenges on December 12, 2023.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 12, 2026. This may change due to patent challenges or generic licensing.

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for VYONDYS 53

International Patents:	30
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VYONDYS 53
What excipients (inactive ingredients) are in VYONDYS 53?	VYONDYS 53 excipients list
DailyMed Link:	VYONDYS 53 at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for VYONDYS 53

Constraining patent/regulatory exclusivity:

INDICATED FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 53 SKIPPING

NDA:

211970

Dosage:

SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for VYONDYS 53

Drug Class	Antisense Oligonucleotide
Physiological Effect	Increased Protein Synthesis

US Patents and Regulatory Information for VYONDYS 53

VYONDYS 53 is protected by one US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on INDICATED FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 53 SKIPPING.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sarepta Theraps Inc	VYONDYS 53	golodirsen	SOLUTION;INTRAVENOUS	211970-001	Dec 12, 2019		RX	Yes	Yes			Y
Sarepta Theraps Inc	VYONDYS 53	golodirsen	SOLUTION;INTRAVENOUS	211970-001	Dec 12, 2019		RX	Yes	Yes

Expired US Patents for VYONDYS 53

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sarepta Theraps Inc	VYONDYS 53	golodirsen	SOLUTION;INTRAVENOUS	211970-001	Dec 12, 2019
Sarepta Theraps Inc	VYONDYS 53	golodirsen	SOLUTION;INTRAVENOUS	211970-001	Dec 12, 2019
Sarepta Theraps Inc	VYONDYS 53	golodirsen	SOLUTION;INTRAVENOUS	211970-001	Dec 12, 2019
Sarepta Theraps Inc	VYONDYS 53	golodirsen	SOLUTION;INTRAVENOUS	211970-001	Dec 12, 2019

International Patents for VYONDYS 53

See the table below for patents covering VYONDYS 53 around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	E498685
Cyprus	1111447
Cyprus	1117475
Germany	602005026386

VYONDYS 53 (golodirsen) Market Dynamics and Financial Trajectory: Revenue Drivers, Channel Build, Pricing, and Competitive Exit Risks

Last updated: June 26, 2026

Executive summary: VYONDYS 53 (golodirsen) is a niche, label-limited Duchenne muscular dystrophy (DMD) therapy sold at an annual list price that has shifted market expectations toward net price discipline, specialty-pharmacy execution, and payer guardrails. Revenue performance has been capped by (i) a narrow exon-skipping genotype slice, (ii) high ongoing treatment cost pressure, (iii) payer restrictions tied to dosing criteria and evidence requirements, and (iv) competitive tension from other exon-skipping programs and emerging next-generation DMD approaches. The financial trajectory remains closely linked to patient identification, payer contracting strength, and the speed of competitive displacement in exon-skipping segments where alternatives offer broader coverage or better payer value.

---

How much does VYONDYS 53 (golodirsen) generate in revenue and what drives the financial trajectory?

Answer: VYONDYS 53’s revenue trajectory is driven by small-patient absolute demand, contracting and reimbursement outcomes at specialty payers, and persistence in a chronic-use model where discontinuation is rare when patients meet continued eligibility criteria.

Demand math: why revenue growth is structurally constrained

• Biology-limited eligibility: Golodirsen is used for DMD patients with a confirmed mutation amenable to exon 53 skipping. That genotype narrows the addressable population in most geographies.
• Chronic treatment profile: Therapy is administered on an ongoing basis, so revenue is influenced by patient start rates, persistence, and dosing continuity, not episodic utilization.
• Clinical substitution risk: Any alternative exon-skipping option covering overlapping genotypes can reduce incremental starts if payers steer patients.

Revenue drivers that matter in year-to-year results

1. Patient identification pipeline
   • Genetic testing penetration and referral to dystrophy centers.
   • Uptake among eligible boys after genotype confirmation.
2. Reimbursement and formulary positioning
   • Specialty pharmacy onboarding and prior authorization throughput.
   • Evidence requirements for continued dosing.
3. Net price outcomes
   • Rebates and patient assistance impact net revenue vs. list.
   • Contract terms in major commercial accounts.
4. Competitive mix effects
   • How quickly competing DMD therapies gain share for exon-skipping subtypes.

---

What is VYONDYS 53’s pricing model and how does it impact net revenue?

Answer: VYONDYS 53’s revenue profile reflects a specialty biologic pricing structure with high list pricing offset by payer-specific contracting. Net revenue depends on rebate intensity, patient assistance mix, and payer coverage rules.

Price mechanics that influence payers and contracting

• High annual acquisition cost: Drives payer utilization management, including:
  • Preauthorization and medical-necessity documentation.
  • Limits on eligible prescribers and centers in some contracts.
• Value arguments and outcomes evidence
  • Payers typically require clinical justification consistent with label language and available evidence.
  • In practice, payer coverage often leans on surrogate endpoints accepted for the therapy’s review history.

How pricing pressure shows up in financial statements

• Net sales growth can lag prescription growth if:
  • Rebates rise, coverage expands unevenly, or
  • Competitive accounts renegotiate tighter terms.
• Revenue volatility can occur when:
  • A major payer plan renews with different terms.
  • Specialty pharmacy distribution changes channel economics.

---

Which companies control VYONDYS 53 market access and distribution economics?

Answer: Market access is shaped by the brand manufacturer’s payer contracts and specialty pharmacy execution. Distribution economics are typically dominated by specialty pharmacy fulfillment, copay assistance management, and payer-administered rebates.

Channel dynamics in rare, high-cost drugs

• Specialty pharmacy role: medication procurement, patient onboarding, benefit investigations, and infusion supply logistics when applicable to local handling requirements.
• Payer role: prior authorization and coverage criteria, step edits where introduced, and claims adjudication that influences whether patients stay on therapy.
• Provider role: dystrophy clinic networks that generate eligible starts.

Market access pattern for DMD exon-skipping therapies

• Access tends to follow a “coverage-first” pathway:
  • Patients start quickly when benefits are preapproved through established payer criteria.
  • Delays occur for documentation gaps around mutation type and ongoing eligibility requirements.

---

What DMD therapies compete with VYONDYS 53 and how do they affect share?

Answer: Golodirsen competes within the DMD exon-skipping landscape where alternative exon-skipping therapies can capture eligible patients depending on the exon profile and payer contracting.

Competitive pressure channels

1. Exon overlap and genotype switching
   • Where a patient’s mutation is amenable to multiple skipping strategies, therapy choice can become payer-driven.
2. Payer steering through coverage criteria
   • Some payers prefer one therapy per exon segment based on contract terms and clinical evidence expectations.
3. Evolution to next-gen approaches
   • Emerging DMD modalities can shift long-horizon expectations for payer willingness to fund incremental exon-skipping programs.

How competition changes the financial trajectory

• When competitors win incremental starts, the brand’s revenue growth slows and net pricing can face downward pressure through renegotiation.
• If competitors take shares in payer-covered accounts, the brand may remain profitable but with limited expansion.

---

When does VYONDYS 53 lose exclusivity or face generic biosimilar-like entry risks?

Answer: VYONDYS 53 is a small-molecule? No. Golodirsen is an antisense oligonucleotide (ASO). That matters because generic entry follows a different regulatory and patent pathway than small-molecule generics. The primary near-term competitive risk remains patent and data exclusivity barriers plus design-around manufacturing/IP rather than classic ANDA-style generic entry timelines.

Exclusivity and entry risk framework (ASO-specific)

• Patent estate controls timeline: multiple patents typically cover:
  • Sequence/chemistry features,
  • Formulations,
  • Manufacturing methods,
  • Therapeutic use.
• “Generic” substitutes are constrained by bioequivalence standards and oligo characterization
  • Even when regulatory frameworks allow abbreviated pathways, demonstrating sameness for ASO chemistry and functional behavior is resource intensive.
• Practical substitution barriers
  • Dosing protocols, stability, and supply-chain qualification raise commercialization friction.

(No exclusivity end dates or patent numbers are presented here because the prompt provides no patent estate, Orange Book listing, or published FDA exclusivity data.)

---

What is the FDA regulatory status of VYONDYS 53 and how does it influence market uptake?

Answer: FDA authorization supports routine prescribing within its labeled patient population. Uptake is governed by coverage criteria more than by dosing expansion.

Regulatory status effects on commercial trajectory

• Label-limited indication: narrows eligible population and drives a slow, case-by-case growth curve.
• Ongoing evidence expectations: payers tend to require continued demonstration of medical necessity aligned with label and clinical practice.
• Pathway and post-marketing dynamics: can influence payer confidence but rarely changes economics quickly because DMD patients remain on therapy over long horizons.

---

What formulations, dosing protocols, and patient eligibility rules constrain sales of VYONDYS 53?

Answer: Sales are constrained by (i) eligibility requirements focused on genotype amenability and (ii) payer documentation rules that determine whether patients receive continued treatment.

Patient eligibility friction points

• Genotype confirmation: coverage commonly requires proof that the mutation is amenable to exon 53 skipping.
• Continuation criteria: ongoing authorization depends on medical-necessity reviews and clinical course.
• Real-world persistence: chronic use favors persistence once approved, but access delays reduce early-cycle growth.

Operational constraints in commercialization

• Infusion and administration logistics: in some markets, clinical administration workflows limit how fast new starts convert to treated patients.
• Supply assurance: high-cost ASO procurement and qualification affect backorders and patient continuity risk, which payers treat as a compliance consideration.

---

How do prior authorization and payer policies shape VYONDYS 53 persistence and discontinuation rates?

Answer: Prior authorization governs start rates; continued authorization governs persistence. For chronic DMD therapy, discontinuation is typically low once payers accept the patient’s ongoing eligibility, but delays can occur at renewals or after documentation cycles.

What payer policy typically does to the revenue line

• Start delay effect: reduces near-term revenue even if therapy is clinically appropriate.
• Renewal effect: if evidence requirements tighten, discontinuations or temporary holds can occur and hit quarterly revenue.
• Contract renegotiation cycles: can cause short-term net revenue changes independent of prescriptions.

---

What patent litigation or Paragraph IV challenges affect the competitive outlook for VYONDYS 53?

Answer: No patent litigation records or Paragraph IV challenges are included here because the prompt provides no jurisdictional litigation dataset, Orange Book patent listing, or court docket references for golodirsen.

---

What is the competitive landscape by geography for VYONDYS 53?

Answer: Geographic revenue depends on regulatory authorization status and payer contracting depth. In practice, DMD exon-skipping therapies scale unevenly across markets based on reimbursement structures and specialty drug governance.

Geography-specific commercialization pattern for rare diseases

• High reimbursement clarity markets: faster starts and higher persistence.
• Fragmented payer systems: slower approvals but sometimes higher volume once contracts settle.
• National health systems: pricing negotiations and reimbursement committees can extend lead times for new starts.

(No country-level revenue allocation is provided because the prompt provides no region-level financial disclosures.)

---

How strong is the patent estate for golodirsen and what does it mean for long-term revenue protection?

Answer: Revenue protection is driven by multiple layers of IP covering ASO identity, formulation, and manufacturing. Without specific patent numbers, jurisdiction, filing, and expiration data, no strength score or timeline can be presented.

What “strong estate” typically means for ASOs

• Multiple, overlapping patents increase the probability that any entrant faces blocking claims.
• Method and manufacturing patents can protect commercial viability even if some claims are weakened.

---

Key Takeaways

• VYONDYS 53 revenue is structurally constrained by exon-53-specific eligibility, making growth dependent on patient identification and payer contracting rather than broad market expansion.
• Net revenue is driven as much by reimbursement and rebate mechanics as by gross pricing.
• Competitive pressure is primarily within exon-skipping DMD therapy segments and can slow incremental starts and trigger contract renegotiations.
• For antisense oligonucleotides, entry risk is dominated by patent and manufacturing/IP barriers, not classic small-molecule generic pathways.
• Financial trajectory is most sensitive to specialty payer policy cycles: prior authorization throughput, continued authorization criteria, and contract renewals.

---

FAQs

1. How does DMD exon-53 patient identification impact VYONDYS 53 quarterly revenue?
2. What reimbursement criteria do payers typically use to approve continued golodirsen dosing?
3. How do specialty pharmacy channel economics affect VYONDYS 53 net sales recognition?
4. What competitive displacement risks exist from other exon-skipping therapies in overlapping genotype subsets?
5. How do ASO patent and manufacturing constraints differ from traditional generic timelines for small molecules?

---

References

1. FDA. Drug approvals and labeling for VYONDYS 53 (golodirsen). U.S. Food and Drug Administration.
2. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
3. EMA. VYONDYS 53 product information (where applicable). European Medicines Agency.